Aurobindo Pharma is currently trading at Rs. 826.00, up by 37.15 points or 4.71% from its previous closing of Rs. 788.85 on the BSE.

aurobindo pharma gets usfdas nod for guaifenesin extended release tablets
Aurobindo Pharma

The scrip opened at Rs. 798.00 and has touched a high and low of Rs. 829.50 and Rs. 792.10 respectively. So far 27014 shares were traded on the counter.

The BSE group ‘A’ stock of face value Rs. 1 has touched a 52 week high of Rs. 829.50 on 27-Jul-2023 and a 52 week low of Rs. 397.30 on 03-Feb-2023.

Last one week high and low of the scrip stood at Rs. 829.50 and Rs. 770.80 respectively. The current market cap of the company is Rs. 46221.77 crore.

The promoters holding in the company stood at 51.83%, while Institutions and Non-Institutions held 39.86% and 8.31% respectively.

Aurobindo Pharma has incorporated a Wholly Owned Step-down Subsidiary namely ‘Auro Pharma LLC’ in Russia, in order to pursue pharma business operations in Russia. The company proposes to make an initial investment of around $10 million.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.